R
Robert Flamini
Researcher at National Institutes of Health
Publications - 15
Citations - 2041
Robert Flamini is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Epilepsy & Lennox–Gastaut syndrome. The author has an hindex of 13, co-authored 13 publications receiving 1567 citations.
Papers
More filters
Journal ArticleDOI
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Orrin Devinsky,Eric D. Marsh,Daniel Friedman,Elizabeth A. Thiele,Linda Laux,Joseph Sullivan,Ian Miller,Robert Flamini,Angus Wilfong,Francis Filloux,Matthew Wong,Nicole Tilton,Patricia L. Bruno,Judith Bluvstein,Julie Hedlund,Rebecca M. Kamens,Jane Maclean,Srishti Nangia,Nilika S. Singhal,Carey A Wilson,Anup D. Patel,Maria Roberta Cilio +21 more
TL;DR: The findings suggest that cannabidiol might reduce seizure frequency and might have an adequate safety profile in children and young adults with highly treatment-resistant epilepsy.
Journal ArticleDOI
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele,Eric D. Marsh,Jacqueline A French,Maria Mazurkiewicz-Bełdzińska,Selim R Benbadis,Charuta Joshi,Paul D Lyons,Adam Taylor,Claire Roberts,Kenneth W. Sommerville,Kenneth W. Sommerville,Boudewjin Gunning,Jacek Gawlowicz,Pawel Lisewski,Maria Mazurkiewicz Beldzinska,Krystyna Mitosek Szewczyk,Barbara Steinborn,Marta Zolnowska,Elaine Hughes,Ailsa McLellan,Selim R. Benbadis,Michael A. Ciliberto,Gary G. Clark,Dennis J. Dlugos,Francis Filloux,Robert Flamini,Jacqueline A. French,Michael Frost,Sheryl R. Haut,Siddarth Kapoor,Sudha Kilaru Kessler,Linda Laux,Paul D. Lyons,Eric D. Marsh,David Moore,Richard P. Morse,Venkatesh Nagaraddi,William E. Rosenfeld,Laurie E. Seltzer,Renée A. Shellhaas,Joseph Sullivan,Elizabeth A. Thiele,Liu Lin Thio,David Wang,Angus A. Wilfong +44 more
TL;DR: Add-on cannabidiol is efficacious for the treatment of patients with drop seizures associated with Lennox-Gastaut syndrome and is generally well tolerated.
Journal ArticleDOI
KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients.
John Millichap,Kristen Park,Tammy Tsuchida,Bruria Ben-Zeev,Lionel Carmant,Robert Flamini,Nishtha Joshi,Paul M. Levisohn,Eric D. Marsh,Srishti Nangia,Vinodh Narayanan,Xilma R. Ortiz-Gonzalez,Marc C. Patterson,Phillip L. Pearl,Brenda E. Porter,Keri Ramsey,Emily L. McGinnis,Maurizio Taglialatela,Molly Tracy,Baouyen Tran,Charu Venkatesan,Sarah Weckhuysen,Edward C. Cooper +22 more
TL;DR: This study provides Class IV evidence that EZO is effective for refractory seizures in patients with epilepsy due to KCNQ2 encephalopathy and assesses the potential of selectiveKCNQ channel openers as targeted treatments.
Journal ArticleDOI
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
Orrin Devinsky,Chloe Verducci,Elizabeth A. Thiele,Linda Laux,Anup D. Patel,Francis Filloux,Jerzy P. Szaflarski,Angus A. Wilfong,Gary D. Clark,Gary D. Clark,Yong D. Park,Laurie Seltzer,E. Martina Bebin,Robert Flamini,Robert T. Wechsler,Daniel Friedman +15 more
TL;DR: This open-label drug trial provides class III evidence for the long-term safety and efficacy of CBD administration in patients with treatment-resistant epilepsy (TRE) associated with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
Journal ArticleDOI
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Linda Laux,E. Martina Bebin,Daniel Checketts,Michael Chez,Robert Flamini,Eric D. Marsh,Ian Miller,Kathryn Nichol,Y. D. Park,Eric Segal,Laurie E. Seltzer,Jerzy P. Szaflarski,Elizabeth A. Thiele,Arie Weinstock +13 more
TL;DR: Results from this interim analysis support add-on CBD as an effective long-term treatment option in patients with Lennox-Gastaut syndrome or Dravet syndrome, with consistent reductions in both seizure types through 96 weeks.